EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study

Tea E Heikkilä, Emilia K Kaiser, Jake Lin, Dipender Gill, Jaakko J Koskenniemi, Ville Karhunen

Diabetologia · 2024

DOI: 10.1007/s00125-024-06267-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, 2024. Verfasst von Tea E Heikkilä und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Mendelian Randomization Analysis, TYK2 Kinase, Interleukin-6. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis We aimed to investigate the genetic evidence that supports the repurposing of drugs already licensed or in clinical phases of development for prevention of type 1 diabetes.

Methods

We obtained genome-wide association study summary statistics for the risk of type 1 diabetes, whole-blood gene expression and serum protein levels and investigated genetic polymorphisms near seven potential drug target genes. We used co-localisation to examine whether the same genetic variants that are associated with type 1 diabetes risk were also associated with the relevant drug target genetic proxies and used Mendelian randomisation to evaluate the direction and magnitude of the associations. Furthermore, we performed Mendelian randomisation analysis restricted to functional variants within the drug target genes.

Results

Co-localisation revealed that the blood expression levels of IL2RA (encoding IL-2 receptor subunit α [IL2RA]), IL6R (encoding IL-6 receptor [IL6R]) and IL6ST (encoding IL-6 cytokine family signal transducer [IL6ST]) shared the same causal variant with type 1 diabetes liability near the corresponding genes (posterior probabilities 100%, 96.5% and 97.0%, respectively). The OR (95% CI) of type 1 diabetes per 1-SD increase in the genetically proxied gene expression of IL2RA , IL6R and IL6ST were 0.22 (0.17, 0.27), 1.98 (1.48, 2.65) and 1.90 (1.45, 2.48), respectively. Using missense variants, genetically proxied TYK2 (encoding tyrosine kinase 2) expression levels were associated with type 1 diabetes risk (OR 0.61 [95% CI 0.54, 0.69]). Conclusions/interpretation Our findings support the targeting of IL-2, IL-6 and TYK2 signalling in prevention of type 1 diabetes. Data availability The analysis code is available at https://github.com/jkoskenniemi/T1DSCREEN , which also includes instructions on how to download the original GWAS summary statistics. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Mendelian Randomization AnalysisTYK2 KinaseInterleukin-6Interleukin-2Genome-Wide Association StudySignal TransductionHumansPolymorphism, Single NucleotideInterleukin-2 Receptor alpha SubunitReceptors, Interleukin-6Genetic Predisposition to Disease

Stichwörter der Autor:innen

Co-localisationIL-2IL-6Mendelian randomisationTYK2Type 1 diabetes

Substanzen

TYK2 KinaseInterleukin-6Interleukin-2TYK2 protein, humanInterleukin-2 Receptor alpha SubunitReceptors, Interleukin-6IL2RA protein, humanIL6 protein, humanIL2 protein, human

Autor:innen und Institutionen

  • Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Turku, Finland.
  • Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Research Unit of Population Health, Faculty of Medicine, University of Oulu, Oulu, Finland. ville.karhunen@mrc-bsu.cam.ac.uk.

Zitieren

APA

Heikkilä, T. E., Kaiser, E. K., Lin, J., Gill, D., Koskenniemi, J. J., & Karhunen, V. (2024). Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study. Diabetologia. https://doi.org/10.1007/s00125-024-06267-5

Vancouver

Heikkilä TE, Kaiser EK, Lin J, Gill D, Koskenniemi JJ, Karhunen V. Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study. Diabetologia. 2024. doi:10.1007/s00125-024-06267-5

BibTeX
@article{Heikkil2024,
  author = {Heikkilä, Tea E and Kaiser, Emilia K and Lin, Jake and Gill, Dipender and Koskenniemi, Jaakko J and Karhunen, Ville},
  title = {Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study},
  journal = {Diabetologia},
  year = {2024},
  doi = {10.1007/s00125-024-06267-5}
}
Kostenlos starten →